Sanofi secures two breakthrough nods in China for rare blood disorders
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
Qfitlia is the first antithrombin (AT)-lowering therapy approved for routine prophylaxis in hemophilia
Ryght AI tackles these hurdles with its AI Site Twin platform
The said certificate is valid for a period of 3 years and opens up the European and other markets for the company's products
Dr Srivastava was selected by an expert jury in recognition of her sustained contributions to renewable chemicals, industrial biotechnology and bioprocess innovation
The reform is set to modernise how medicines are developed, authorised, and made available across the EU
The new powder formulation gives children and adults living with Rett syndrome greater flexibility and choice in dose volume and taste
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
Clinical trial enrollment has long been a bottleneck in drug development
Subscribe To Our Newsletter & Stay Updated